Sanofi makes another bolt-on with Kadmon
The “left field but logical” buy sees Sanofi gaining a graft-versus-host disease therapy to add to its transplant offering.
The sellside’s most controversial products
Drugs prompting the most divergent opinions on outlook include Pfizer and Vir’s Covid-19 offerings and Biogen’s Aduhelm.
Fortunes diverge for solo drug launchers
A solo drug launch is a testing time for a small company, made even tougher by the pandemic.
UK asserts its independence with first Covid-19 vaccine nod
The UK’s swift authorisation of Biontech and Pfizer’s Covid-19 shot has attracted both praise and concern.
